Browse by category

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity. The reviews, which examine the effects of three weight loss drugs known as GLP-1 receptor antagonists, have found that all three drugs result in clinically meaningful weight loss compared w

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss,...

A population-wide study presented at the Annual Meeting of the European Association for the Study of Diabetes, Vienna, reports that half...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

An analysis of social media posts and a remote study of individuals with obesity who reported using semaglutide and tirzepatide, has...

Semaglutide used in the diabetes drug Ozempic and the weight-management drug Wegovy is not associated with an increased risk for suicidal...

Semaglutide specifically reduces the symptoms of alcohol use disorder (AUD), according to researchers at the University of Oklahoma...

Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...

Semaglutide 2.4mg (Wegovy) reduces cardiovascular events in patients with overweight or obesity and pre-existing cardiovascular disease...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...